Here's How Much Extra Money Pfizer Will Make From Vaccines for Younger Kids This Year

Moderna is holding off on filing for Emergency Use Authorization (EUA) for its COVID-19 vaccine in children ages six to 11. The company made this decision after the U.S. Food and Drug Administration (FDA) extended its review of Moderna's EUA filing in adolescents ages 12 to 17.

This leaves Pfizer (NYSE: PFE) and its partner BioNTech (NASDAQ: BNTX) clearly in the driver's seat in the COVID-19 vaccine market for children. The two companies won U.S. EUA for their vaccine in kids ages five to 11 last week.

But how much extra money Pfizer will make from its COVID-19 vaccine for younger kids this year? The answer might surprise you.

Source Fool.com